Abstract
INTRODUCTION
Cancer immunotherapeutics, in particular monoclonal antibody-based products
and vaccines, are transforming the cancer treatment market and providing a
whole new arsenal of weapons. The introduction of the first monoclonal
antibody product to the worldwide market for the treatment of cancer in 1998
initiated a cascade of additional monoclonal antibody products for the
treatment of cancer that continues unabated. Average annual growth of
monoclonal antibody products has stayed in the double digits since the late
1990s. In 2006, antibodies were the single largest class of therapeutics in
clinical development with the exception of vaccines. Essentially every biotech
and pharmaceutical company, large or small, has a research program that
centers on monoclonal antibodies.
The first dedicated off-the-shelf (not patient-specific) cancer vaccine was
introduced to the market in 2006. Merck' s Gardasil (quadrivalent human
papillomavirus recombinant vaccine) was approved by the FDA in June 2006 for
the prevention of cervical cancer associated with human papillomavirus (HPV).
The approval of Gardasil marks the first time the FDA approved a designated
therapeutic cancer vaccine. Gardasil was approved in the E.U. in September
2006. This report discusses the impact of these new and growing classes of
cancer drugs, their influence on the market in terms of treatment and
revenues, and how they will complement and/or compete with existing products.
The information and analysis presented in this report on cancer immunotherapy
products are important assets in decision-making for managers involved in
business development, marketing, market research, product development, mergers
and acquisitions, licensing, business management, investment banking and for
consultants to the pharmaceutical and biotechnology industries. The study
provides a comprehensive analysis of the current markets for cancer
immunotherapy products and, in particular, the market potential of promising
drugs, vaccines and technologies under development.
SCOPE OF STUDY
This report contains:
- Analyses of products and applications in the cancer immunotherapy sector,
including biological response modifiers (cytokines), monoclonal antibody-based
products, therapeutic vaccines and other cancer immunotherapies.
- An overview of the global market, including historical data for cancer
treatment and therapies, the latest market trends, and 5-year forecasts and
estimates through 2012
- A section on industry structure with strategies employed by Big Pharma as
well as top-selling drug patent expirations and how this relates to the
overall pharmaceutical industry and biotechnology companies in particular
- Sections on products and applications with synopses of more than 100
cancer immunotherapy drug and vaccine products, including those currently
marketed and those in Phase III or later development
- Analyses of patents within the past few decades
- Profiles for important businesses.
METHODOLOGY
The base year for this study is 2006. Figures are based on revenue figures at
the manufacturers' level and are projected at 2006 dollar value; that is,
inflation is not computed into the projection figures.
This study was prepared from information obtained from product managers,
marketing strategists, research executives and others at leading
pharmaceutical and biotechnology companies that compete in the market for
cancer immunotherapeutics or which have products in development for this
market.
INFORMATION SOURCES
The information and analyses presented in this report are based on an
extensive survey of the biotechnology and pharmaceutical industries as well as
a detailed examination of published literature and reports obtained from
regulatory authorities, medical research institutions, pharmaceutical trade
associations and national and world health organizations. Key information from
the business literature was used as to obtain expert opinion on commercial
potential and market sizes from industry professionals.
View Cart
